Skip to main content
SpringerLink
Log in

PCOS from Lifestyle to the Use of Inositol and Insulin Sensitizers

  • Chapter
Frontiers in Gynecological Endocrinology

Part of the book series: ISGE Series ((ISGE))

Abstract

PCOS patients are typically characterized by chronic anovulation, hyperandrogenism, and polycystic ovaries, and these aspects are frequent in a high percentage of women during the reproductive life. PCOS frequently show overweight and/or obesity and are characterized by a higher production of androgens and reduced sensitivity to insulin. In fact it is of great importance to note that more than 40–45% of all PCOS patients show overweight up to obesity and that these patients have a modest up to an exaggerated hyperinsulinism in response to the standard oral glucose tolerance test (OGTT). What is relevant to point out is that such reduced insulin sensitivity can be observed also in 10–15% of the normal weight PCOS, thus confirming that hyperinsulinism can show up not only in relation to obesity or to excess of fat tissue but also as an intrinsic abnormal ability to control glucose metabolism.

Recent data clearly demonstrated that reduced insulin sensitivity can be gained with a specific attention to lifestyle, including not only a diet but also certain degree of physical activity. However, a specific effect on hyperinsulinemia can be achieved using glucose sensitizer drugs, such as metformin, so that to reduce the negative modulation exerted by hyperinsulinemia on the reproductive axis as well as on neuroendocrine control of reproduction with relevant effects also on adrenal function and neurosteroid production.

The evolution of therapeutical approach to PCOS proposed in recent years the use of inositol in two of the isomers at present available, that is myo-inositol (MYO) and D-chiro-inositol (DCI). These two compounds are tightly linked one to the other since MYO is transformed by an epimerase in DCI, having each tissue its own conversion rate, likely due to the specific needs for the two different molecules. In general both these compounds work as specific modulators of the intracellular second messenger activated by the insulin linkage with its own membrane receptor.

Recent data demonstrated also that integrative administration of MYO in lean PCOS ameliorated insulin response to OGTT and that both MYO and DCI reduced insulin response to OGTT in overweight or obese PCOS. Both isomers have been demonstrated to improve also ovarian function and LH response to GnRH stimulation, typically abnormal in PCOS patients. Though impossible to state what of the two isomers play the main role, it appears clear that the metabolic impairment(s) are great part of the casual factor(s) of the abnormal reproductive function in PCOS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carmina E, Lobo RA (1999) Polycystic ovary syndrome: arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 84:1897–1899

    Article  CAS  PubMed  Google Scholar 

  2. Zborowski JV, Cauley JA, Talbott EO et al (2000) Bone mineral density, androgens, and the polycystic ovary: the complex and controversial issue of androgenic influence in female bone. J Clin Endocrinol Metab 85:3496–3506

    Article  CAS  PubMed  Google Scholar 

  3. Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds) Polycystic ovary syndrome. Blackwell, Boston, MA, pp 337–384

    Google Scholar 

  4. Polson DW, Adams J, Wadsworth J, Franks S (1988) Polycystic ovaries-a common finding in normal women. Lancet 1:870–872

    Article  CAS  PubMed  Google Scholar 

  5. Azziz R, Carmina E, Dewailly D, Androgen Excess Society et al (2006) Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237–4245

    Article  CAS  PubMed  Google Scholar 

  6. Palomba S, Falbo A, Zullo F, Orio F (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 30:1–50

    Article  CAS  PubMed  Google Scholar 

  7. Deligeoroglou E, Kouskouti C, Christopoulos P (2009) The role of genes in the polycystic ovary syndrome: predisposition and mechanism. Gynecol Endocrinol 25:603–609

    Article  CAS  PubMed  Google Scholar 

  8. Hirschberg AL (2009) Polycystic ovary syndrome, obesity and reproductive implications. Womens Health 5:529–540

    Google Scholar 

  9. Genazzani AD, Petraglia F, Pianazzi F, Volpogni C, Genazzani AR (1993) The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol Endocrinol 7:33–41

    Article  CAS  PubMed  Google Scholar 

  10. Vrbikova J, Hainer V (2009) Obesity and polycystic ovary syndrome. Obes Facts 2:26–35

    Article  PubMed  Google Scholar 

  11. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S (2009) Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 19:398–405

    Article  CAS  PubMed  Google Scholar 

  12. Nelson VL, Qin KN, Rosenfield RL et al (2001) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86:5925–5933

    Article  CAS  PubMed  Google Scholar 

  13. Plouffe L Jr (2000) Disorders of excessive hair growth in the adolescent. Obstet Gynecol Clin North Am 27:79–99

    Article  PubMed  Google Scholar 

  14. Dunaif A, Green G, Futterweit W, Dobrjansky A (1990) Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in polycystic ovary syndrome J. Clin Endocrinol Metab 70:699–704

    Article  CAS  Google Scholar 

  15. Barbieri RL (1990) The role of adipose tissue and hyperinsulinemia in the development of hyperandrogenism in women. In: Frisch RE (ed) Adipose tissue and reproduction. Karger, Basal, pp 42–57

    Google Scholar 

  16. Conway GS, Jacobs HS, Holly JM, Wass JA (1990) Effects of LH, insulin, insulin-like growth factor I and insulin-like growth factor small binding protein I in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 33:593–603

    Article  CAS  Google Scholar 

  17. Dunaif A, Givens JR, Haseltine F et al (1992) The polycystic ovary syndrome. Blackwell, Boston, MA

    Google Scholar 

  18. Mattsson LA, Gullberg G, Hamberger L, Samsioe G, Silverstolpe G (1984) Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease. Fertil Steril 42:579–584

    CAS  PubMed  Google Scholar 

  19. Muniyappa R, Montagnani M, Koh KK, Quon MJ (2007) Cardiovascular actions of insulin. Endocr Rev 28:463–491

    Article  CAS  PubMed  Google Scholar 

  20. Carmina E (2009) Cardiovascular risk and events in polycystic ovary syndrome. Climacteric 12(Suppl 1):22–25

    Article  PubMed  Google Scholar 

  21. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375(9710):181–183

    Article  PubMed  Google Scholar 

  22. Cornier MA, Dabelea D, Hernandez TL et al (2008) The metabolic syndrome. Endocr Rev 29:777–822

    Article  CAS  PubMed  Google Scholar 

  23. International Diabetes Federation (2006) The International Diabetes Federation consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf

  24. Gluek CJ, Papanna R, Wang P (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52:908–915

    Article  Google Scholar 

  25. Apridonidze T, Essah PA, Iuorno MJ (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929–1935

    Article  CAS  PubMed  Google Scholar 

  26. Dockras A, Bochner M, Holinrake E (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106:131–137

    Article  Google Scholar 

  27. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61:946–951

    Article  CAS  PubMed  Google Scholar 

  28. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHughPemu KP, Zborowski JV, Remsberg KE (2000) Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20:2414–2421

    Article  CAS  PubMed  Google Scholar 

  29. Luscher TF, Richard V, Tshudi M, Yang ZH, Boulanger C (1990) Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol 15:519–527

    Article  CAS  PubMed  Google Scholar 

  30. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC (1990) Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81:491–497

    Article  CAS  PubMed  Google Scholar 

  31. Legro RS (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24:302–312

    Article  PubMed  Google Scholar 

  32. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146

    Article  CAS  PubMed  Google Scholar 

  33. Palomba S, Russo T, Orio F Jr et al (2006) Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 21:457–465

    Article  CAS  PubMed  Google Scholar 

  34. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 18:774–800

    CAS  PubMed  Google Scholar 

  35. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647–654

    Article  CAS  PubMed  Google Scholar 

  36. Tang T, Glanville J, Hayden CJ et al (2006) Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 21:80–89

    Article  PubMed  Google Scholar 

  37. Knowler WC, Barrett-Connor E, Fowler SE, Diabetes Prevention Program Research Group et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403

    Article  CAS  PubMed  Google Scholar 

  38. Kitabchi AE, Temprosa M, Knowler WC et al (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54:2404–2414

    Article  PubMed  Google Scholar 

  39. Palomba S, Falbo A, Orio F, Zullo F (2008) Insulin sensitizing agents and reproductive function in polycystic ovary syndrome patients. Curr Opin Obstet Gynecol 20:364–373

    Article  PubMed  Google Scholar 

  40. Hsueh AJ, Billig H, Tsafriri A (1994) Ovarian follicle atresia: a hormonally controlled apoptotic process. Endocr Rev 15:707–724

    CAS  PubMed  Google Scholar 

  41. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ (2009) Insulin sensitizing drugs or weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update 15:57–68

    Article  CAS  PubMed  Google Scholar 

  42. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O (2004) Metformin dministration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 81:114–119

    Article  CAS  PubMed  Google Scholar 

  43. Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM (2007) Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 23:146–152

    Article  CAS  PubMed  Google Scholar 

  44. La Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De Leo V (1999) Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 72:985–989

    Article  PubMed  Google Scholar 

  45. Patel K, Coffler MS, Dahan MH et al (2003) Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab 88:5456–5461

    Article  CAS  PubMed  Google Scholar 

  46. Cosma M, Swiglo BA, Flynn DN et al (2008) Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 93:1135–1142

    Article  CAS  PubMed  Google Scholar 

  47. Budak E, Fernández Sánchez M, Bellver J, Cerveró A, Simón C, Pellicer A (2006) Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3–36 with the reproductive system. Fertil Steril 85:1563–1581

    Article  CAS  PubMed  Google Scholar 

  48. Saltiel AR (1990) Second messengers of insulin action. Diabetes Care 13:244–256

    Article  CAS  PubMed  Google Scholar 

  49. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G (1999) Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340:1314–1320

    Article  CAS  PubMed  Google Scholar 

  50. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM (2008) Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 24:139–144

    Article  CAS  PubMed  Google Scholar 

  51. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Iuorno MJ, Nestler JE (2006) Altered D-Chiro-Inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 29:300–305

    Article  CAS  PubMed  Google Scholar 

  52. Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE (2004) Metformin therapy increases insulin-stimulated release of D-chiroinositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:242–249

    Article  CAS  PubMed  Google Scholar 

  53. Genazzani AD, Ricchieri F, Prati A, Santagni S, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG (2012) Differential insulin response to myo-inositol administration in obese PCOS patients. Gynecol Endocrinol 28:969–973

    Article  CAS  PubMed  Google Scholar 

  54. Galazis N, Galazi M, Atiomo W (2011) D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol 27:256–262

    Article  CAS  PubMed  Google Scholar 

  55. Larner J (2002) D-chiro-Inositol—its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 3:47–60

    Article  PubMed Central  PubMed  Google Scholar 

  56. Harwood K, Vuguin P, DiMartino-Nardi J (2007) Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res 68:209–217

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE (2002) Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 8:417–423

    Article  PubMed  Google Scholar 

  58. Gerli S, Mignosa M, Di Renzo GC (2003) Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 7:151–159

    CAS  PubMed  Google Scholar 

  59. Chiu TTY, Rogers MS, Law ELK, Briton-Jones CM, Cheung LP, Haines CJ (2002) Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 6:1591–1596

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Modena, Italy

    Alessandro D. Genazzani, Alessia Prati, Giulia Despini, Giulia Marini & Federica Ricchieri

Authors
  1. Alessandro D. Genazzani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessia Prati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giulia Despini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giulia Marini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Federica Ricchieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro D. Genazzani .

Editor information

Editors and Affiliations

  1. International Society of Gynecological Endocrinology, Pisa, Italy

    Andrea R. Genazzani

  2. Department of Obstetrics and Gynaecology, Mater Dei Hospital, Birkirkara, Malta

    Mark Brincat

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Genazzani, A.D., Prati, A., Despini, G., Marini, G., Ricchieri, F. (2014). PCOS from Lifestyle to the Use of Inositol and Insulin Sensitizers. In: Genazzani, A.R., Brincat, M. (eds) Frontiers in Gynecological Endocrinology. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-319-03494-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-03494-2_7

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-03493-5

  • Online ISBN: 978-3-319-03494-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation